Eisai expands marketing regions for Belviq for Obesity
Eisai announced that it has expanded the marketing and supply agreement it concluded with Arena Pharmaceuticals, Inc. in July 2010 for the antiobesity agent Belviq (lorcaserin hydrochloride). While the previous agreement granted Eisai exclusive rights to market and distribute lorcaserin in 21 countries throughout the Americas, the expanded agreement now includes most countries and territories worldwide, most notably the European Union, Japan and China (and excluding South Korea, Taiwan, Australia, New Zealand, Israel).
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins